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Although the dissemination of urothelial cancer cells is supposed to be a major cause of the multicentricity of
urothelial tumors, the mechanism of implantation has not been well investigated. Here, we found that cancer cell
clusters from the urine of patients with urothelial cancer retain the ability to survive, grow, and adhere. By using
cell lines and primary cells collected from multiple patients, we demonstrate that △Np63α protein in cancer cell
clusters was rapidly decreased through proteasomal degradation when clusters were attached to the matrix,
leading to downregulation of E-cadherin and upregulation of N-cadherin. Decreased △Np63α protein level in
urothelial cancer cell clusters was involved in the clearance of the urothelium. Our data provide the first evidence
that clusters of urothelial cancer cells exhibit dynamic changes in △Np63α expression during attachment to the
matrix, and decreased △Np63α protein plays a critical role in the interaction between cancer cell clusters and the
urothelium. Thus, because △Np63α might be involved in the process of intraluminal dissemination of urothelial
cancer cells, blocking the degradation of △Np63α could be a target of therapy to prevent the dissemination of
urothelial cancer.
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Urothelial cell carcinomas are often multifocal and synchronous at
primary diagnosis, and 17% of patients with upper urinary tract
urothelial carcinomas reportedly present with concomitant bladder
cancer [1]. In addition, approximately one half of the patients develop
intravesical recurrences after transurethral resection (TUR) of non–
muscle-invasive bladder cancer [2]. Two theories have been proposed
to explain the multifocality of urothelial cell carcinoma: the field
cancerization hypothesis and the monoclonality hypothesis. The field
cancerization hypothesis proposes that tumors arise from different
clones, probably because of severe carcinogenic insults to the urinary
tract. On the other hand, the monoclonality hypothesis proposes that
the multifocal tumors originate from a single transformed cell and
that the tumor cells spread by intraluminal implantation or
intraepithelial migration [3,4].Dissemination of the cancer cells through urine is supported by
clinical observations and the molecular profiling of the cancers. The
risk of bladder cancer recurrence is 30% to 51% in upper urinary tract
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(1.8%-7.5%) of UUTC recurrence after TUR for bladder cancers [7,8].
The risk increases to 6% to 20% (15- to 22-fold) in patients with
vesicoureteral reflux [9,10]. In addition, coincidental genetic alterations in
UUTC and bladder cancer are reported in the same patients [11–13].
Thus, there is evidence that cancer cells disseminate through the urinary
stream, although the biological interaction between the urothelium and
urothelial cancer cells is poorly understood.
The TP63 gene is a member of the TP53 gene family. The TP63
gene contains two transcriptional start sites that are used to generate
transcripts encoding two isoforms. One contains an N-terminal
transactivation (TA) domain (TAp63), but the others do not
(△Np63). Both genes can be alternatively spliced to generate
proteins with three different C-termini: α, β, and γ [14,15]. p63 is
expressed in embryonic ectoderm and in the nuclei of basal cells of
many epithelial tissues in the adult, including the urothelium, and
plays an important role in the development and homeostasis of the
epithelium [16,17]. In normal adult urothelium as well as urothelial
cancer cells, △Np63 is predominantly abundant compared with
TAp63 [18–21]. The functional role of p63 in cancer is controversial.
Studies using bladder cancer cell lines revealed that suppression of
△Np63α induces N-cadherin expression and promotes motility and
invasiveness [21,22]. The expression of △Np63α is lower in
muscle-invasive cancer than non–muscle-invasive cancer [17,20].
These reports indicate that △Np63α is an oncosuppressor. On the
other hand, because △Np63 expression in muscle-invasive cancer
correlates with a worse prognosis [17,20,23], △Np63α can be
considered an oncogene.
The concept that the collective behavior of a group of cancer cells
defines malignant function is rapidly developing. Within the group, cells
remain cohesive by expressing cell–cell junction molecules. These groups
are represented by collective cancer cell invasion [24] and the clusters of
circulating tumor cells [25]. In breast cancer, circulating tumor cell
clusters derived frommulticellular groupings of primary tumor cells retain
cell–cell contact through plakoglobin-dependent intercellular adhesion,
which greatly contributes to the metastatic spread of cancer [26]. We
demonstrate here that cancer cell clusters in urine are viable, able to
proliferate, and can attach to the cell matrix. By using bladder cancer cell
lines and primary cultured cancer cells, we further demonstrate that
△Np63α expression levels change dramatically during attachment and
play a critical role in implantation.
Materials and Methods
Ethics Statement
The institutional ethics committees at the Osaka Medical Center
for Cancer and Cardiovascular Diseases (OMCCCD) approved this
study. Human urothelial cancer specimens and human urothelial
tissues were collected from patients treated at the Department of
Urology, OMCCCD. Animal studies were approved by the
OMCCCD Institutional Animal Care and Use Committee and
were performed in compliance with institutional guidelines.
Cells and Cell Culture
Bladder cancer cell lines RT4, 5637, and J82 and an immortalized
urothelial cell line, SV-HUC-1, were purchased from the American
Type Culture Collection (ATCC, Manassas, VA). All cell lines were
authenticated by short tandem repeat DNA profiling using GenePrint
10 System (Promega, Madison, WI). RT4 cells were cultured at 37°Cunder 5% CO2 in McCoy’s 5A; 5637 and J82 cells were cultured in
RPMI 1640; and SV-HUC-1 cells were cultured in F12-K medium
supplemented with 10% fetal bovine serum. Clusters from each cell
line were prepared by seeding 4 × 105 cells in 2 ml of medium in
poly-2-hydroxyethyl methacrylate–coated dishes prepared by dissolv-
ing 5 mg/ml poly-2-hydroxyethyl methacrylate (Sigma-Aldrich, Saint
Louis, MO) in 95% ethanol and then adding 500 μl of the solution to
six-well culture dishes. Clusters were subjected to further experiments
24 hours after seeding. Culture conditions are referred to as “2D’” for
conventional adhesive culture and as “3D” for multicellular spheroid
culture in suspension.
Primary cultures of urothelial cancer cells were prepared according
to the cancer-tissue–originated spheroid (CTOS) method [27,28].
Briefly, surgical samples or xenograft tumors were mechanically
dissociated, partially digested with liberase DH (Roche Applied
Science, Mannheim, Germany), and filtered through cell strainers.
Fragments on 100-μm or 40-μm cell strainers (BD Falcon, Franklin
Lakes, NJ) were collected. CTOSs were cultured in StemPro hESC
human embryonic stem cell culture medium (Invitrogen, Carlsbad,
CA). All bladder and upper urinary tract tumor samples were
confirmed as urothelial carcinoma by institutional pathologists.
Patient-derived xenografts of BC23 and UT35 were described in
our previous report [28]. In experiments on attachment, CTOSs were
cultured on type I collagen (Cellmatrix, Nitta Gelatin, Osaka,
Japan)–coated dishes for 20 to 24 hours. Culture conditions are
referred to as “floating” for spheroid cultures in suspension and
“attached” for culture after attachment of floating spheroids.
Urine Samples
Urine samples were collected from patients diagnosed with urothelial
cancer by cytology. Voided urine or urine from catheters was collected
and centrifuged, and sediments were recovered and cultured in StemPro
hESC human embryonic stem cell culture medium (Invitrogen).
Subsequently, cell clusters in the culture medium were picked up using
a pipette and further cultured in Matrigel growth factor reduced (BD
Biosciences, Bedford, MA) or type I collagen–coated dishes for growth or
adhesion assays, respectively.
Western Blotting
Cells were lysed with cell lysis buffer (10 mM Tris [pH 7.4], 0.15
MNaCl, 1%NP40, 0.25% sodium deoxycholate, 0.05MNaF, 2 mM
EDTA, 0.1% SDS, 2 mM NaVO4, 10 μg/ml aprotinin, 10 μg/ml
leupeptin, and 1 mM PMSF). Western blotting was performed as
previously described [28]. Primary antibodies raised against ΔNp63
(anti-p40) were obtained from Calbiochem (Merck Millipore,
Darmstadt, Germany); E-cadherin and N-cadherin, from Abcam
(Cambridge, MA); and β-actin, from Sigma-Aldrich.
Immunohistochemistry and Analysis
Immunohistochemistry was performed as previously described
[28]. Primary antibodies against total p63 (4A4), ΔNp63 (anti-p40),
and E-cadherin were obtained from Santa Cruz Biotechnology
(Dallas, TX), Calbiochem, and Abcam, respectively. For assessment
of the percentage of p63-positive cells in spheroids, the number of
nuclei staining for p63 expression and the total number of nuclei were
counted in each spheroid in each group. Intense ΔNp63 nuclear
staining was scored as 2; moderate, as 1; and negative, as 0. The
ΔNp63 score was then calculated by multiplying the staining
intensity by the rate of positivity. For evaluation of the
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according to preceding reports [29,30]; positive staining for E-cadherin
was defined as the proportion of tumor cells with membranous
staining N90%. For whole-mount immunostaining, cell lines and cell
clusters were fixed and permeabilized with 4% paraformaldehyde/
PBS containing 1% Triton X-100 at 4°C for 1 hour. After blocking
with 5% goat serum/PBS-T for 1 hour, cells were incubated with
anti-p63 antibody (4A4) (Santa Cruz Biotechnology) and Ki67 (Leica
Biosystems, Newcastle, UK) overnight, then with Alexa-488 and
Alexa-555 conjugated secondary antibody (Moleculer Probes,
Eugene, OR, USA) overnight. After counterstaining with
Hoechst33342 (Molecular Probes), cells were mounted with
FluorSave Reagent (Calbiochem, Merck millipore). Images of
fluorescent cells were obtained using confocal microscopy (TCS
SPE, Leica Microsystems, Wetzlar, Germany).
Flow Cytometry
Spheroids derived from 5637 cells or CTOSs were dissociated into
single cells using 0.25% trypsin/EDTA acid (Life Technologies,
Carlsbad, CA, USA). For cell death assays, single cells were incubated
with 1 μg/ml of propidium iodide (PI) (Molecular Probes) at 37°C for
15 minutes without fixation. Subsequently, flow cytometry was
conducted using an Attune Acoustic Focusing Cytometer (Applied
Biosystems, Foster City, CA), and the results were analyzed using
FlowJo software (Tree Star, Ashland, OR).
Semiquantitative reverse transcription polymerase chain
reaction (RT-PCR)
Total RNA was extracted from cell lines or CTOSs cultured under
floating or attached conditions using TRIzol Reagent (Life
Technologies). For semiquantitative RT-PCR, 1 μg of total RNA
was reverse transcribed to obtain cDNA using Superscript III
(Invitrogen) according to the manufacturer’s protocol. PCRs were
performed using the Gene Amp VR PCR System (Life Technologies).
The primer sequences and PCR cycle numbers are shown in
Supplementary Tables S1 and S2, respectively.
Proteasome Inhibition Experiments
Approximately 80 spheroids derived from 5637 cells or CTOSs were
plated in 24-well tissue culture dishes (Corning Inc., Corning, NY) or
type I collagen (Cellmatrix)–coated dishes, and cultured with 0.1%
dimethyl sulfoxide or the indicated dose of MG132 (Sigma-Aldrich) or
SB216763 (Sigma-Aldrich). The spheroids were collected after 7 hours
for cell lines and after 20 hours for CTOSs, and then the proteins from
lysed cells were subjected toWestern blotting. For the spheroids cultured
in collagen-coated dishes, collagenwas removed by incubation at 37°C for
10 minutes with collagenase type IV (Worthington Biochemical
Corporation, Lakewood, NJ) before collection.Figure 1. Cancer cell clusters in the urine of patients with bladder can
staining of primary bladder urothelial tumors (upper row), phase contr
urine derived from the same patients (lower row). HG, high grade. Sca
from the urine of a patient (BC289) with urothelial cancer and cul
indicated. Scale bar, 200 μm. (C) Immunostaining for Ki67 in cell clu
cancer. (D) Phase contrast images of cell clusters collected from th
adhesive conditions. The culture periods are indicated. Scale bar, 200
cell clusters prepared from surgically resected urothelial tumors (BC2
flow cytometry at day 2 (F). Red lines are for PI staining, and gray s
images of PI (G) and histograms of flow cytometry at day 2 (H) withUrothelium Clearance Assay
GFP-expressing SV-HUC-1 cells or primary human urothelial cells
were seeded on 96-well plates with or without coating with type I collagen
(Cellmatrix). Cells were maintained in culture until confluent (24-36
hours after plating). In co-culture experiments, a spheroidwas placed onto
a confluent urothelial monolayer. Images under bright-field and
fluorescent microscopy were captured using an OLIMPUS IX70
microscope (OLUMPUS, Tokyo, Japan). To quantify the clearance of
urothelial cells by a spheroid, the area devoid of the urothelial monolayer
was measured and divided by the initial area of the spheroid.
Plasmid Construction and Gene Transfer
To construct the ΔNp63α expression vector, the BamHI-NotI
fragment of pCDNA3.1hygro/deltaNp63alpha1xflag (Addgene,
Cambridge, MA) was transferred to pPBiresPuro to make pPB/
deltaNp63alpha1xflag. For short hairpin RNA vectors targeting p63,
two targeting sequences, ACATGTGAGTGACGATGAT (#1) or
AACCATGAGCTGAGCCGTGAATT (#2), were cloned into pPB
shRNA [31] to make pPB/shp63 #1 and pPB/shp63 #2. EGFP was
introduced by subcloning into pPB-Ubc.eGFP-neo [32]. The vectors
were co-transfected with pCMV-hyPBase [32] by lipofection, using
X-tremeGENE HP DNA Transfection Reagent (Roche Applied
Science) according to manufacturer’s protocol. After transfection,
cells permanently expressing the transfected genes were selected with
G-418 (Roche Applied Science) or puromycin.
Statistical Analysis
Statistical analysis was conducted using GraphPad Prism 6
(GraphPad Software, San Diego, CA). Data are expressed as means
with standard deviation. Statistical significance was tested using
unpaired t test for single comparisons or one-way analysis of variance
followed by Tukey test for multiple comparisons. A value of P b .05
was considered statistically significant.
Results
Cancer Cell Clusters in the Urine of Patients with Urothelial
Cancer Retain the Ability to Grow and Adhere
We first examined the urine samples collected from patients with
urothelial cancer to assess the status of cancer cells in the urine. We
collected cancer cell clusters, known from clinical cytology to exist in
patients’ urine, from patients’ urine (Figure 1A, Supplementary
Figure 1). Some of the clusters (8 of 28 clusters from 5 patients,
28.6%) grew as spheroids in vitro with Ki67-positive proliferating
cells (Figure 1, B and C). In addition, 5 of 12 clusters from 3 patients
(41.7%) were able to attach to type I collagen–coated dishes
(Figure 1D). Thus, the cancer cells also existed as clusters in the urine
of patients with urothelial cancer and were able to grow and attach to
the matrix. When cancer cells detach from the extracellular matrix,cer retain the ability to grow and adhere.(A) Hematoxylin and eosin
ast images (middle row), and Papanicolaou staining of sediments in
le bar, 100 μm. (B) Phase contrast images of cell clusters collected
tured in Matrigel growth factor reduced. The culture periods are
sters collected from the urine of a patient (BC287) with urothelial
e urine of a patient (BC297) with urothelial cancer and cultured in
μm. (E, F) Cell death assay by PI incorporation with single cells or
98). Bright-field and fluorescent images of PI (E) and histograms of
hades are for nonstained cells. (G, H) Bright-field and fluorescent
a bladder cancer cell line (5637). Scale bar, 200 μm.
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that cancer cells from urothelial cancers, as well as other cancers from
patient tumors, can be stably prepared and cultured by maintaining
cell–cell contacts throughout the preparation and culture procedure
using a CTOS method [27,28,31,35]. When the clusters of cancer
cells prepared from surgically resected urothelial tumors were
dissociated into single cells, the dead cells with PI-positive staining
drastically increased after 24 hours in culture under floating
conditions compared with intact clusters (Figure 1, E and F ). The
clusters formed spheroids with smooth surface after 24 hours
(Figure 1E). The same phenomenon was observed in the bladder
cancer cell line 5637 (Figure 1, G and H ). These results suggest that
urothelial cancer cells in the urine have a better chance of surviving as
clusters than as single cells under floating conditions.
△Np63α Is Highly Expressed in the Nucleus of Relatively
Differentiated Bladder Cancer Cell Lines in Spheroids
Compared with 2D-Cultured Cells
We focused on△Np63α because it was reported to play a role in
motility and invasion as well as N-cadherin expression in urothelial
cancer cells [21,22]. In addition, decreased staining levels of△Np63
are reported to correlate with recurrence of non–muscle-invasive
bladder cancer after TUR [17,36]. We confirmed this in patients
from our institution by using a different antibody than that previously
used, showing that the staining score was higher in patients without
recurrence (Figure 2, A and B; Supplementary Table 3). All the
tumors analyzed were primary, solitary, pathological T1, and less than
3 cm in diameter without concomitant carcinoma in situ. None of the
patients received intravesical therapy after TUR.
To analyze the △Np63α status in the clusters, we first analyzed
multiple bladder cancer cell lines with various differentiation levels:
RT4 (well), 5637 (moderately), and J82 (poorly). The shape of the
clusters differed among cell lines. RT4 and 5637 formed spheroids
with a smooth surface, whereas J82 formed irregular clusters
(Figure 2C ). The protein levels of △Np63 in 3D clusters and in
2D cells were assessed by Western blotting. All isoforms of △Np63
(α, β, and γ) were detected in the spheroids of RT4 and 5637 cells,
with the α isoform having the highest expression level (Figure 2D).
The levels of α isoforms were higher in cells in 3D than 2D cultures.
In contrast, only low levels of the γ isoform were detected in J82,
and the levels were the same in 3D clusters and 2D cells. When
spheroids of the 5637 cells were attached to the dish, they quickly
grew out as monolayer cells (Figure 2E ). The levels of △Np63α
decreased over time (Figure 2F ). Immunocytochemistry revealed
that p63 was localized in the nucleus of all the cells in the 5637
spheroids, whereas nuclear p63 was lost in many of the 2D cells, with
some cells retaining the signal in the cytoplasm (Figure 2G ). Thus,
△Np63α was highly expressed in the nucleus of relatively
differentiated bladder cancer cells in 3D spheroids compared with
cells in 2D cultures.Figure 2. Δ Np63α expression in a patient with bladder cancer and th
conditions.(A) Representative images of the indicated intensity of N
(B) Comparison of Np63 staining scores between patients with or wi
(C) Phase contrast images of the indicated cell lines under 2D or 3D c
the indicated cell lines cultured under 3D or 2D conditions. ACTB, β-a
spheroid placed on a culture dish. Scale bar, 200 μm. (F) Western
immunostaining of a 5673-derived spheroid and of a spheroid 24 ho△Np63α Expression Was High in Primary Cultured
Spheroids and Decreased after Attachment to the Cell Matrix
We further examined whether the phenomena observed in the
5637 cell line are common in primary cultured cancer cells. The
spheroids prepared using the CTOS method from patient urothelial
cancers or patient-derived xenografts (PDXs) retain original charac-
teristics [28,37]. CTOSs were directly prepared from operatively
resected bladder or upper urinary tract tumors or PDX tumors. When
CTOSs were placed in collagen-coated dishes, almost all of them
attached to the surface and then started to form a monolayer
(Figure 3A). Floating CTOSs showed higher levels of p63 than
matrix-attached CTOSs in all cases examined (Figure 3, B and C ). It
should be noted that even the cancer cells in CTOSs that did not
directly attach to the collagen matrix showed decreased p63
expression (Figure 3B). Western blotting showed decreased expres-
sion of △Np63α after matrix attachment in all primary CTOSs
examined, whereas the levels of △Np63α varied among samples
(Figure 3D). When the attached CTOSs were forcedly detached
from the collagen matrix, they again formed spheroids, and△Np63α
expression was recovered (Figure 3E ). Thus, in clinical samples,
the levels of △Np63α were high in floating clusters and then
decreased when attached to the matrix, and the expression levels were
highly reversible.
It is reported that △Np63α decreases after induction of
differentiation [38]. Using RT-PCR for various cytokeratins (CKs),
we examined whether the decrease in △Np63α was due to
differentiation after attachment. CK5 and CK14 are basal cell
markers, and CK18 and CK20 are differentiation markers [39].
Because changes in the expression of these CKs after attachment vary
among the cell lines and CTOSs (Supplementary Figure 2A),
differentiation alone cannot explain the decrease in △Np63α
expression after attachment.
Decrease in △Np63α Expression after Attachment to the
Matrix Was Due to Degradation by the Proteasome
We investigated the mechanisms of the attachment-induced
decrease in △Np63α protein levels in urothelial cancer cell clusters.
In contrast to the protein levels, △Np63 mRNA levels were about
the same in floating clusters and 2D-attached RT4 and 5637 cells,
and were quite low under both conditions in J82 cells (Figure 4A). In
all the CTOSs examined, mRNA levels were about the same in
floating and attached CTOSs (Figure 4B).
△Np63α is reportedly degraded by the ubiquitin-proteasome
system after DNA damage [40] or induction of differentiation [38].
After phosphorylation by glycogen synthase kinase 3 (GSK3),
△Np63α is recognized by ubiquitin ligases such as Fbw7 [41]. We
investigated the involvement of the proteasome in the attachmen-
t-induced decrease in△Np63α protein levels in urothelial cancer cell
clusters. The decrease in △Np63α protein levels after attachment
was suppressed by the proteasome inhibitor MG132 (Figure 4C ). Ane dynamic change in the expression in vitro under 2D or 3D culture
p63 immunostaining in pT1 bladder cancers. Scale bar, 100 μm.
thout intravesical recurrence after transurethral resection. *P b .05.
onditions. Scale bar, 200 μm. (D) Western blot analysis of △Np63 in
ctin. (E) Time course images showing attachment of a 5673-derived
blot analysis of △Np63 in 5637 cells in E. (G) Whole mount p63
urs after attachment. Scale bar, 75 μm.
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Figure 3. Dynamic change in ΔNp63α expression in primary cultured spheroids after attachment to the cell matrix.(A) Images of phase
contrast (upper row, scale bar 200 μm) or hematoxylin and eosin (lower row, scale bar 100 μm) of CTOSs prepared from urothelial cancer
(BC246) cultured in floating conditions or attached on a type I collagen gel. (B) Images showing p63 expression by immunohistochemistry
of a CTOS under floating or attached conditions (BC250). Scale bar, 50 μm. A sagittal section is shown for the attached CTOSs. Dotted
lines indicate the surface of the gel (A, B). (C) Percentage of p63-positive cells in various CTOSs. Each dot indicates one CTOS. *P b .05,
**P b .01. (D) Western blot of Np63 in CTOSs cultured under floating (FL) or attached (AT) conditions. CTOSs were prepared from
surgically resected tumors. (E) Western blot of Np63 in CTOSs from two PDX tumors (BC23x and UT35x). CTOSs were attached to type I
collagen gels and then detached from the gels and cultured for 0.5 (D0.5) and 4 hours (D4).
580 Yoshida et al. Neoplasia Vol. 17, No. 7, 2015inhibitor of GSK3, SB216763, suppressed the decrease in△Np63α
protein levels after attachment (Figure 4D). The same effect was
observed in CTOSs fromMG132 and SB216763 (Figure 4,C andD).
Thus, the decrease in △Np63 protein levels after attachment to the
matrix is generally due to degradation through the proteasome.
Decreased △Np63α Protein Levels in Urothelial Cancer Cell
Clusters Parallels Cadherin Switching
We examined the effect of decreased △Np63α on the molecular
events related to the attachment to the matrix. We focused on
cadherins as being downstream of △Np63α because forced
expression of△Np63α is reported to negatively regulate N-cadherin
expression and suppress motility and invasion in 2D cell lines [21,22].
We first assessed the relationship between the expression levels of
△Np63α and E-cadherin in clinical samples. Immunohistochemis-
try of non–muscle-invasive tumors revealed that cases negative forE-cadherin expression had lower△Np63 expression levels (Figure 5,
A and B). Thus, the levels of E-cadherin parallel those of△Np63α in
clinical samples. Next, we examined whether the levels of cadherins
change under different culture conditions. 5637 cells in 3D spheroids
expressed higher levels of E-cadherin and lower levels of N-cadherin
than 2D cells with regards to both mRNA and protein levels (Figure 5,
C and D). Meanwhile, the gene expression of other epithelial-to-
mesenchymal transition (EMT)–related genes was not enriched in
2D cells (Supplementary Figure 2B). When CTOSs were attached
to the matrix, E-cadherin signals decreased markedly in cells within
CTOSs (left panels) in parallel with the decline in p63 (right panels)
(Figure 5E ). Here again, even the cancer cells in CTOSs that did
not directly attach to the collagen matrix showed decreased
E-cadherin expression. Taken together, changes in the △Np63α
levels during attachment of the cancer cell clusters were related to the
cadherin levels.
Figure 4. Decrease in △Np63α protein levels after attachment to the matrix was due to degradation by the proteasome. (A, B)
Semiquantitative RT-PCR for Np63 mRNA in bladder cancer cell lines (A) and CTOSs from patient tumors or patient xenograft tumors
(B). FL, floating and AT, attached conditions. (C, D) Western blot of ΔNp63 in the 5637 cell line and UT35x CTOSs under floating or
attached conditions, with or without the proteasome inhibitor MG132 (C) or the GSK3 inhibitor SB216763 (SB) (D). MG132 1 μM for 5637
and 0.2 μM for UT35x; SB216763 10 μM for 5637 and 5 μM for UT35x.
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Involved in the Clearance of Urothelium
According to the dissemination theory, floating cancer cells first
implant in the sheet of urothelial cells covering the wall of the urinary
tract. Implantation of ovarian cancer cell clusters on mesothelial cells
was previously demonstrated to be accompanied by exclusion of the
mesothelium by the cancer cells [42]. Using a similar assay, we
investigated the interaction between the clusters of urothelial cancer
cells and the urothelium. When clusters of the 5637 bladder cancer
cell line were placed onto a sheet of GFP-labeled SV-HUC-1 (normal
immortalized human urothelial cell), the clusters or spheroids
attached to the dish by clearing the urothelial cells (Figure 6A).
The clearance of the urothelium and attachment to the dish by the
clusters proceeded over time (Figure 6B). Spheroids prepared from
primary bladder cancer cells also attached to the dish by clearing the
primary cultured urothelial cells (Supplementary Figure 3).
Next, we generated 5637 cell lines in which△Np63α was forcedly
overexpressed or suppressed (Figure 6C ). Both cell lines formed the
same spheroids as control vector-transfected cells, but the
△Np63α-overexpressing cells were more roundly shaped under
2D conditions (Supplementary Figure 4, A and B). E-cadherin levels
were slightly higher in △Np63α-overexpressing cell spheroids but
were clearly lower in the p63 knockdown cell spheroids (Figure 6C ).
Reciprocally, the N-cadherin levels in spheroids were lower in the
△Np63α-overexpressing cells and higher in the p63 knockdown
cells (Figure 6C ). The differences in △Np63α expression levels
between 3D and 2D conditions were observed also in the
△Np63α-overexpressing and the p63 knockdown cells (Supple-
mentary Figure 4, C and D). We examined whether the decrease in
△Np63α has a function in the clearance of urothelium and
attachment to the matrix underneath the urothelium. Urothelium
clearance by the △Np63α-overexpressing 5637 spheroid cells was
suppressed compared with the control vector-transfected cells(Figure 6,D and E). On the contrary, clearance by the p63 knockdown
spheroid cells was enhanced (Figure 6, F and G). Thus, the decrease in
△Np63α in urothelial cancer cell clusters is involved in the clearance of
the urothelium and attachment of the underlying matrix.
Discussion
We demonstrate that△Np63α expression levels in urothelial cancer
cell clusters dramatically decrease during the attachment to the cell
matrix. The decrease in △Np63α plays a critical role in cadherin
switching, one of the aspects of the EMT in which cells shift
expression from E-cadherin to N-cadherin [43]. Cadherin switching
has a profound effect on tumor phenotype. In clinical reports, lower
E-cadherin levels and higher N-cadherin levels correlate with
intravesical recurrence of bladder cancer after TUR [29,30]. Taken
together with the clinical reports, our results suggest a model of
intraluminal dissemination; clusters of cancer cells detach from the
primary site of urothelial cancer, drift in the urine, and attach to
distant urothelium, resulting in decreased expression of △Np63α
followed by a cadherin switch and becoming the origin of
disseminated foci.
The ability of epithelial cells to reversibly change their phenotype is
referred to as epithelial plasticity [44]. Tumor metastasis is an
example of epithelial plasticity in which tumor cells undergo EMT
and acquire a migratory and invasive phenotype and disseminate,
whereas the reversion of EMT, mesenchymal-to-epithelial transition,
is essential to settle the metastasis in the target organ [45]. Mutations
or deletions in TP63 are rarely reported in malignant tumors,
including urothelial cancers [46,47], whereas gene manipulation of
△Np63α revealed that suppression of △Np63α promotes EMT in
human bladder cancer cells [21,22]. As we demonstrate in our study,
the expression levels of △Np63α were flexibly regulated in the
dissemination model, and △Np63α might be a key molecule for
epithelial plasticity in urothelial cancer.
Figure 5. Decreased △Np63α protein levels in urothelial cancer cell clusters parallels cadherin switching.(A) Representative images of
positive or negative patterns of ΔNp63 and E-cadherin immunostaining in pT1 bladder cancers. Scale bar, 100 μm. (B) Comparison of
ΔNp63 staining scores between patient samples with positive or negative E-cadherin expression (same cohort of patients as in Figure 2B).
*P b .05 (C, D) Semiquantitative RT-PCR (C) and Western blot (D) of E-cadherin and N-cadherin in the 5637 cell line cultured under the
indicated conditions. (E) Immunohistochemical staining for E-cadherin (left panels) and p63 (right panels) in a CTOS under floating or
attached conditions (BC246). A sagittal section is shown for the attached CTOSs. Dotted lines indicate the surface of the gel.
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the urothelium, we applied a model developed for peritoneal
dissemination of ovarian cancer: an ovarian cancer-mesothelium
clearance assay [42,48]. Using this assay, Davidowitz et al. reported
that the ability to clear mesothelium in clusters of ovarian cancer cells
is increased when the mesenchymal character is artificially rendered to
the cancer cells [48]. In this study, we observed cadherin switching
during the attachment of cancer cell clusters to the cell matrix, which was
regulated by changes in endogenous △Np63α levels. Among the
EMT-like events, cadherin switching might play a central role in
promoting clearance of urothelium by clusters of urothelial cancer cells.
The inner lumen of the urinary tract is covered by urothelium,
which is a transitional epithelium consisting of distinct types of cell
layers including basal, intermediate, and superficial [39]. In this
study, we applied a monolayer culture of immortalized urothelial cells
(SV-HUC-1) as a model of the epithelium so that the interaction
between cancer cell clusters and superficial-layer cells was not
assessed. Indeed, experiments using reconstituted urothelium from
porcine urinary bladders revealed that the cancer cell line would not
implant on umbrella cells but would implant on the cells in the basaland intermediate layers after removing the umbrella cells [49].
Conditions of the urothelium, such as injury by operative procedures,
might affect implantation.
The p63 protein levels are regulated by ubiquitin-dependent
degradation through the proteasome [47,50]. Several E3 ligases
for p63 and kinases that modulate the binding of E3 ligases to
p63 proteins have been identified. In this study, a decrease in
△Np63α protein levels was suppressed by inhibition of the
proteasome. Because translocation of △Np63α from the nucleus
to the cytoplasm was observed after attachment of the clusters in the
5637 cell line and the decrease in △Np63α was suppressed by a
GSK3 inhibitor, the degradation might be through the pathway
reported by Galli et al.; MDM2 binds △Np63α in the nucleus,
promoting its translocation to the cytoplasm where p63 is targeted for
degradation by the Fbw7 E3-ubiquitin ligase [41]. Degradation of
△Np63α is reportedly promoted by DNA damage [40,41] or
induction of differentiation [38,41]. Because we did not observe clear
evidence of differentiation after attachment (Supplementary Figure
2A), it is unlikely that the degradation of △Np63α is due to
differentiation induced by attachment.
Figure 6. Degradation of △Np63α in bladder cancer cell clusters after attachment was involved in the clearance of urothelium.(A) Time
course images of urothelium clearance by bladder cancer cell clusters from the 5637 cell line. Bright-field images (left column) and
fluorescent images (right column) of GFP-labeled SV40-immortalized normal human urothelial cells (SV-HUC-1). Scale bar, 200 μm. (B)
Quantification of urothelial clearance by bladder cancer cell clusters in A. (C) Western blot analysis of E-cadherin (Ecad), N-cadherin
(Ncad), and ΔNp63 in the spheroids of 5637 cells transfected with expression vectors ΔNp63α (p63) and p63 shRNA (sh/p63#1 and sh/
p63#2). Vct, empty vector; Ctr, scrambled shRNA. (D) Bright-field images (left column) and fluorescent images (right column) showing
clearance of urothelium at the indicated time points by control vector or ΔNp63α-overexpressing 5637-derived spheroids. Scale bar, 200
μm. (E) Quantification of urothelium clearance in D. *P b .01. (F) Bright-field images (left column) and fluorescent images (right column)
showing clearance of urothelium at the indicated time points by control vector (shCtr) or p63-silenced (sh/p63#1) 5637-derived spheroids.
Scale bar, 200 μm. (G) Quantification of urothelium clearance in F. *P b .01.
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to the ubiquitin-proteasome system for △Np63α degradation was
not identified. Direct integrin signaling or secondary events, such as
cytoskeletal remodeling, might be candidates for the upstream
signaling pathway. It is intriguing that the decrease in △Np63
occurred not only in the cells directly attached to the matrix but also
in cells within the clusters apart from the attachment interface with
the matrix. These results suggest the existence of an intercellular
communication pathway within the cluster. The downstreamsignaling pathway, which transfers the decrease in △Np63α levels
to cadherin switching or later attachment and migration, is also
unknown. Transcription factors involved in EMT were not increased
in this study (Supplementary Figure 2B), suggesting that mechanisms
other than typical EMT are involved. Although it requires further
study, blocking the degradation of △Np63 could be a target of
therapy for preventing dissemination of urothelial cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.07.004.
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